Pfizer Sues Metsera and Novo Nordisk Over Disputed Obesity Drug Merger
Pfizer has escalated its battle for Metsera, filing a lawsuit in Delaware's Court of Chancery to block the biotech firm from terminating their $7.3 billion merger agreement. The pharmaceutical giant alleges both Metsera and rival bidder Novo Nordisk engaged in contractual breaches and improper interference.
The legal action seeks immediate injunctive relief, including a temporary restraining order to preserve the deal. Pfizer contends Novo Nordisk's competing $8.5 billion offer fails to meet the legal standard for a superior proposal, citing unresolved regulatory hurdles that could derail the transaction.
Market observers note the timing coincides with intensifying competition in the lucrative obesity drug sector. Pfizer's bid already cleared early antitrust review, while Novo Nordisk's offer remains subject to regulatory uncertainty—a key differentiator in the court's assessment of deal viability.
